It is what the published clinical evidence shows about each peptides mechanism, half-life, FDA approval status, and demonstrated effects
References PubMed Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults PubMed Once-daily CJC-1295 normalizes growth in GHRH knockout mouse PubMed Ipamorelin, the first selective growth hormone secretagogue PMC Beyond the androgen receptor: GH secretagogues in body composition management PubMed Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers PubMed Ipamorelin GH pulse kinetics and timing studies CDC Vaccine administration: subcutaneous route (angle/site
Tesamorelin typically produces measurable visceral fat reduction over 12 to 26 weeks of consistent therapy, with the Phase III trial data showing 15 percent reduction at 26 weeks
Imprinted gene in postnatal growth role
Together, we can achieve your health goals without compromising your well-being
Ipamorelin works differently, its a growth hormone secretagogue that targets ghrelin receptors not GHRH pathways